Details for Patent: 12,178,819

Which drugs does patent 12,178,819 protect, and when does it expire?

Patent 12,178,819 protects GLYXAMBI and TRADJENTA and is included in two NDAs.

This patent has ninety patent family members in thirty-six countries.

Summary for Patent: 12,178,819

Title:	DPP IV inhibitor formulations
Abstract:	The present invention relates to pharmaceutical compositions of DPP IV inhibitors with an amino group, their preparation and their use to treat diabetes mellitus.
Inventor(s):	Anja Kohlrausch, Patrick Romer, Gerd Seiffert
Assignee:	Boehringer Ingelheim International GmbH
Application Number:	US17/319,325
Patent Claim Types: see list of patent claims	Composition; Compound; Dosage form;

Drugs Protected by US Patent 12,178,819

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Boehringer Ingelheim	GLYXAMBI	empagliflozin; linagliptin	TABLET;ORAL	206073-001	Jan 30, 2015		RX	Yes	No	12,178,819		Y
Boehringer Ingelheim	GLYXAMBI	empagliflozin; linagliptin	TABLET;ORAL	206073-002	Jan 30, 2015		RX	Yes	Yes	12,178,819		Y
Boehringer Ingelheim	TRADJENTA	linagliptin	TABLET;ORAL	201280-001	May 2, 2011	AB	RX	Yes	Yes	12,178,819		Y

International Family Members for US Patent 12,178,819

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	060755
Argentina	079930
Austria	E480228
Australia	2007247193
Brazil	PI0711179
Brazil	PI0722388
Canada	2649922